Dusenbery K E, Carlson J W, LaPorte R M, Unger J A, Goswitz J J, Roback D M, Fowler J M, Adcock L L, Carson L F, Potish R A
Department of Therapeutic Radiology/Radiation Oncology, University of Minnesota Hospital and Clinics, Minneapolis 55455.
Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):989-98. doi: 10.1016/0360-3016(94)90393-x.
PURPOSE/OBJECTIVE: To report the long-term results of vulvectomy, node dissection, and postoperative nodal irradiation using a midline vulvar block in patients with node positive vulvar cancer.
From 1971 through 1992, 27 patients with carcinoma of the vulva and histologically involved inguinal lymph nodes were treated postoperatively with radiation therapy after radical vulvectomy and bilateral lymphadenectomy (n = 25), radical vulvectomy and unilateral lymphadenectomy (n = 1), or hemivulvectomy and bilateral lymphadenectomy (n = 1). Federation Internationale de Gynecologic et d'Obstetrique stages were III (n = 14), IVA (n = 8), and IVB (n = 5) squamous cell carcinoma. Inguinal lymph nodes were involved with tumor in all patients (average number positive = 4, range 1-15). Postoperative irradiation was directed at the bilateral groin and pelvic nodes (n = 19), unilateral groin and pelvic nodes (n = 6), or unilateral groin only (n = 1). These 26 patients had the midline blocked. In addition, one patient received irradiation to the entire pelvis and perineum. Doses ranged from 10.8 to 50.7 Gy (median 45.5) with all patients except 1 receiving > or = 42.0 Gy.
Actuarial 5-year overall survival and disease-free survival estimates were 40% and 35%, respectively. Recurrences developed in 63% (17/27) of the patients at a median of 9 months from surgery (range 3 months to 6 years) and 15 of these have died; two patients with recurrences are surviving at 24 and 96 months after further surgery and radiation therapy. Central recurrences (under the midline block) were present in 13 of these 17 patients (76%), either as central only (n = 8), central and regional (n = 4), or central and distant (n = 1). Additionally, three patients developed regional recurrences and one patient developed a concurrent regional and distant relapse. One patient developed a squamous cell cancer of the anus under the midline block 54 months after the initial vulvar cancer and an additional patient developed transitional cell carcinoma of the ureter (outside the radiation field) 12 months after diagnosis. Factors associated with a decreased relapse-free survival included increasing Federation Internationale de Gynecologic et d'Obstetrique stage (p = 0.01) and invasion of the tumor into the subcutaneous (SC) fat or deep soft tissue (p = 0.05). Chronic lower extremity edema developed in four patients, but there have been no other complications.
Radical vulvectomy has often been considered sufficient central treatment for vulvar carcinoma, with postoperative irradiation directed only to the nodes. Although designed to protect the radiosensitive vulva, use of a midline block in this series resulted in a 48% (13/27) central recurrence rate, much higher than the 8.5% rate previously reported with this technique. Routine use of the midline block should be abandoned and, instead, postoperative irradiation volumes should be tailored to the individual patient.
目的/目标:报告采用中线外阴阻滞对腹股沟淋巴结阳性的外阴癌患者进行外阴切除术、淋巴结清扫术及术后淋巴结照射的长期结果。
1971年至1992年期间,27例外阴癌且组织学检查显示腹股沟淋巴结受累的患者,在根治性外阴切除术和双侧淋巴结清扫术(n = 25)、根治性外阴切除术和单侧淋巴结清扫术(n = 1)或半侧外阴切除术和双侧淋巴结清扫术(n = 1)后接受了术后放疗。国际妇产科联盟(FIGO)分期为III期(n = 14)、IVA期(n = 8)和IVB期(n = 5)的鳞状细胞癌。所有患者的腹股沟淋巴结均有肿瘤累及(平均阳性数 = 4,范围1 - 15)。术后放疗针对双侧腹股沟和盆腔淋巴结(n = 19)、单侧腹股沟和盆腔淋巴结(n = 6)或仅单侧腹股沟(n = 1)。这26例患者进行了中线阻滞。此外,1例患者接受了全盆腔和会阴照射。剂量范围为10.8至50.7 Gy(中位剂量45.5 Gy),除1例患者外,所有患者接受的剂量≥42.0 Gy。
精算5年总生存率和无病生存率估计分别为40%和35%。63%(17/27)的患者出现复发,中位复发时间为术后9个月(范围3个月至6年),其中15例患者死亡;2例复发患者在进一步手术和放疗后分别存活24个月和96个月。这17例患者中有13例(76%)出现中线复发(在中线阻滞区域下方),可为仅中线复发(n = 8)、中线和区域复发(n = 4)或中线和远处复发(n = 1)。此外,3例患者出现区域复发,1例患者同时出现区域和远处复发。1例患者在初次外阴癌诊断54个月后,在中线阻滞区域下方发生肛管鳞状细胞癌,另1例患者在诊断12个月后发生输尿管移行细胞癌(在放疗野之外)。与无复发生存率降低相关的因素包括国际妇产科联盟分期增加(p = 0.01)以及肿瘤侵犯皮下(SC)脂肪或深部软组织(p = 0.05)。4例患者出现慢性下肢水肿,但无其他并发症。
根治性外阴切除术通常被认为是外阴癌充分的中心治疗方法,术后放疗仅针对淋巴结。尽管设计用于保护放射敏感的外阴,但本系列中使用中线阻滞导致中心复发率为48%(13/27),远高于此前报道的该技术8.5%的复发率。应放弃常规使用中线阻滞,相反,术后放疗范围应根据个体患者进行调整。